Intellia Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Intellia Therapeutics (Nasdaq: NTLA) said management will participate in three upcoming investor fireside chats: Bank of America Securities Health Care Conference on May 12, 2026 (3:40 p.m. PT, Las Vegas); RBC Capital Markets Global Healthcare Conference on May 20, 2026 (2:35 p.m. ET, New York); and Jefferies Global Healthcare Conference on June 3, 2026 (4:55 p.m. ET, New York).
All sessions will be webcast live with replays available for approximately 90 days on Intellia’s Events and Presentations page at intelliatx.com.
Positive
- None.
Negative
- None.
News Market Reaction – NTLA
In the May 5 session, NTLA declined 4.04%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that management will be participating in fireside chats at the following upcoming investor conferences:
- Bank of America Securities Health Care Conference
Date: Tuesday, May 12, 2026
Fireside Chat Time: 3:40 p.m. PT
Location: Las Vegas
- RBC Capital Markets Global Healthcare Conference
Date: Wednesday, May 20, 2026
Fireside Chat Time: 2:35 p.m. ET
Location: New York
- Jefferies Global Healthcare Conference
Date: Wednesday, June 3, 2026
Fireside Chat Time: 4:55 p.m. ET
Location: New York
The fireside chats will be webcast live. To join the webcasts, please visit the Events and Presentations page of the Investors & Media section on Intellia’s website at intelliatx.com. Replays of the webcasts will be available on the same page for approximately 90 days following the events.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com
Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicommunications.com